Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2021

View Archived Issues

aTyr Pharma describes monoclonal antibodies targeting neuropilin-2

Canopy Growth Corp. describes new cannabinoid CB1/CB2 receptor modulators

MAPK 8 inhibitors patented by Wuhan LL Science and Technology Development

Shanghai De Novo Pharmatech discloses G12C mutant GTPase KRAS inhibitors

Shanghai Newsky Biotechnology presents new PLA2G7 inhibitors

Fulcrum Therapeutics' FTX-6058 could be a disease-modifying treatment for sickle cell disease

Novel antibody-drug conjugate OBI-998 targets SSEA-4 for cancer therapy

CXCL17 protein expression is associated with tumor aggressiveness in cSCC

TST-005, a bifunctional fusion protein with promising antitumor activity in preclinical models

Phase IIb data for R-21 malaria vaccine adjuvanted with Matrix-M

Collaboration promotes new antimalarial drug development

FDA grants accelerated approval to Zynlonta for relapsed or refractory large B-cell lymphoma

Merck KGaA presents c-KIT inhibitors with strong antitumor activity in GIST

Phase III MELODY study of nirsevimab to prevent RSV infection in infants meets primary endpoint

Zyesami and Veklury studied within new ACTIV-3 Critical Care study for severe COVID-19

Neurodevelopmental and biomarker data for RGX-121 in a phase I/II study for severe MPS II

PHI-101 studied in phase I trial for relapsed or refractory AML

Vivet opens enrollment in phase I/II study of VTX-801 gene therapy for Wilson's disease

Phase II trial evaluates ALX-148 with pembrolizumab for advanced HNSCC

New phase I/II trial evaluates OBI-3424 for relapsed or refractory T-ALL and T-LBL

Immunome reports preclinical data on SARS-CoV-2 antibody cocktail IMM-BCP-01

Bayer initiates first-in-human study of BAY-2666605 in metastatic melanoma and advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...